

January 17, 2006

Press Release

Merus BV Closes Series A Financing

Utrecht, The Netherlands – January 17, 2006 – Merus B.V., a privately held biomedical company, today announced the completion of a financial package with Aglaia Oncology Seed Fund B.V. This funding will allow the Company to execute the plans toward its research and business objectives for the coming three years.

Allocation of the funds will be towards the further validation of the Oligoclomics™ technology and product platform. Oligoclomics™ is a novel concept whereby a mixture of several human therapeutic antibodies, directed to a common antigen, e.g. a virus or a tumor cell, are produced from a single cell clone.

Oligoclomics™ are thought to mimic the body's natural polyclonal antibody response, which is in many instances known to be more efficacious than monoclonal antibody treatments. The technology is believed to give the therapeutic antibody field a new impetus by providing clinically more efficacious treatments.

Merus anticipates partnering with a selected group of biopharmaceutical companies with vested investments in the therapeutic monoclonal antibody field and which have strategic interests in Oligoclomics™ product development.

Aglaia is a venture firm dedicated to identifying groundbreaking opportunities in cancer research and to contributing to the expansion of its ventures into next phases. Aglaia's team, expertise and network in the field of oncology research and product development further support the growth of Merus.

=====

For further information contact:

Merus B.V.

Ton Logtenberg, Ph.D. - CEO
t.logtenberg@Merus.nl
www.merus.nl

Aglaia Biomedical Ventures B.V.
info@aglaia-biomedical.com
www.aglaia-biomedical.com